Cargando…

A Budget Impact Model to Estimate the Environmental Impact of Adopting RESPIMAT(®) Re-usable in the Nordics and Benelux

INTRODUCTION: The healthcare sector contributes 5–8% of the global greenhouse gas emissions. Global and regional organizations and governments have started to design and implement measures to reduce global greenhouse gas emissions in the healthcare sector, e.g. by green public procurement policies a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ortsäter, Gustaf, Borgström, Fredrik, Soulard, Stéphane, Miltenburger, Carolin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6860470/ https://www.ncbi.nlm.nih.gov/pubmed/31625130 http://dx.doi.org/10.1007/s12325-019-01114-1

Ejemplares similares

Incorporating the Environmental Impact into a Budget Impact Analysis: The Example of Adopting RESPIMAT(®) Re-usable Inhaler
por: Ortsäter, Gustaf, et al.
Publicado: (2019)

The Director general of CERN to the Benelux countries
por: CERN Press Office. Geneva
Publicado: (1966)

Patient perceptions of the re-usable Respimat(®) Soft Mist™ inhaler in current users and those switching to the device: A real-world, non-interventional COPD study
por: Dreher, Michael, et al.
Publicado: (2021)

Budget impact analysis of the adoption of new hypertension guidelines in Colombia
por: Guevara-Cuellar, Cesar Augusto, et al.
Publicado: (2018)

Improving usability and maintaining performance: human-factor and aerosol-performance studies evaluating the new reusable Respimat inhaler
por: Dhand, Rajiv, et al.
Publicado: (2019)

Standards for aseptic techniques in medical aesthetic practices in the Benelux: Consensus recommendations
por: Baharlou, Samira, et al.
Publicado: (2022)

Reduced Environmental Impact of the Reusable Respimat(®) Soft Mist™ Inhaler Compared with Pressurised Metered-Dose Inhalers
por: Hänsel, Michaela, et al.
Publicado: (2019)

Adoption of Initial Budget
Publicado: (1954)

Safe Use of Epidural Corticosteroid Injections: Recommendations of the WIP Benelux Work Group
por: Van Boxem, Koen, et al.
Publicado: (2018)

Procedure for the Adoption of the CERN Budget
Publicado: (1956)

Epidemiological Predictive Modeling of COVID-19 Infection: Development, Testing, and Implementation on the Population of the Benelux Union
por: Šušteršič, Tijana, et al.
Publicado: (2021)

Use of Respimat(®) Soft Mist™ Inhaler in COPD patients
por: Anderson, Paula
Publicado: (2006)

Assessment of Patient Experiences with Respimat(®) in Everyday Clinical Practice
por: Taube, Christian, et al.
Publicado: (2020)

Long-Term Pollen Monitoring in the Benelux: Evaluation of Allergenic Pollen Levels and Temporal Variations of Pollen Seasons
por: de Weger, Letty A., et al.
Publicado: (2021)

Asthma patients prefer Respimat(®) Soft Mist™ Inhaler to Turbuhaler(®)
por: Hodder, Rick, et al.
Publicado: (2009)

The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes
por: Anzueto, Antonio, et al.
Publicado: (2015)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
por: Ko, Dennis T., et al.
Publicado: (2018)

The potential impact of immunization campaign budget re-allocation on global eradication of paediatric infectious diseases
por: Fitzpatrick, Tiffany, et al.
Publicado: (2011)

Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States
por: Shah, Anshul, et al.
Publicado: (2021)

Adoption of RTS, S malaria vaccine for children younger than 5 years in Rwanda: A budget impact analysis
por: Ndikumukiza, Cyrille, et al.
Publicado: (2021)

Tiotropium Respimat® improves physical functioning in chronic obstructive pulmonary disease
por: Rau-Berger, Heike, et al.
Publicado: (2010)

Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis
por: Halpin, David MG, et al.
Publicado: (2015)

Patients’ perspectives and preferences in the choice of inhalers: the case for Respimat(®) or HandiHaler(®)
por: Dekhuijzen, Pieter Nicolaas Richard, et al.
Publicado: (2016)

The Respimat(®) Soft Mist Inhaler: Implications of Drug Delivery Characteristics for Patients
por: Iwanaga, Takashi, et al.
Publicado: (2019)

Bioinformatics as a driver, not a passenger, of translational biomedical research: Perspectives from the 6(th )Benelux bioinformatics conference
por: Azuaje, Francisco J, et al.
Publicado: (2012)

Estimated Budget Impact of Adopting the Affordable Care Act’s Required Smoking Cessation Coverage on United States Healthcare Payers
por: Baker, Christine L., et al.
Publicado: (2016)

Detainees, staff, and health care services in immigration detention centres: a descriptive comparison of detention systems in Sweden and in the Benelux countries
por: Puthoopparambil, Soorej J., et al.
Publicado: (2016)

Development of Respimat(®) Soft Mist™ Inhaler and its clinical utility in respiratory disorders
por: Dalby, Richard N, et al.
Publicado: (2011)

Impact of orphan drugs on Latvian budget
por: Logviss, Konstantins, et al.
Publicado: (2016)

Budget impact analysis of adopting primary care–based case detection of chronic obstructive pulmonary disease in the Canadian general population
por: Mountain, Rachael, et al.
Publicado: (2023)

BNAIC 2016: 28th Benelux conference on artificial intelligence, Amsterdam, The Netherlands, November 10-11, 2016, revised selected papers
por: Bosse, Tibor, et al.
Publicado: (2017)

Artificial intelligence: 30th Benelux conference, BNAIC 2018, 'S-Hertogenbosch, The Netherlands, November 8-9, 2018, revised selected papers
por: Atzmueller, Martin, et al.
Publicado: (2019)

CMS inputs on ML models re-usability
por: Ngadiuba, Jennifer
Publicado: (2022)

Heritage projects, archivization and re-usability concerns
por: Banerjee, Swagato, et al.
Publicado: (2019)

Anthelmintic resistance. An overview of the situation in the Nordic countries
por: Ihler, Carl Fredrik
Publicado: (2010)

Efficacy and safety of tiotropium Respimat(®) SMI in COPD in two 1-year randomized studies
por: Bateman, Eric, et al.
Publicado: (2010)

Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial
por: Dahl, Ronald, et al.
Publicado: (2015)

In vitro dose comparison of Respimat(®) inhaler with dry powder inhalers for COPD maintenance therapy
por: Ciciliani, Anna-Maria, et al.
Publicado: (2017)

The impact of climate change on crop mix shift in the Nordic region
por: Nainggolan, Doan, et al.
Publicado: (2023)

The Impact of Nordic Walking Pole Length on Gait Kinematic Parameters
por: Russo, Luca, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5kekdenk0l3v9vfi6fgef249uh